Trial Profile

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients with Symptomatic Generalized Myasthenia Gravis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemdisiran (Primary) ; Pozelimab (Primary)
Indications Myasthenia gravis
Focus Registrational; Therapeutic Use
Acronyms NIMBLE
Sponsors Regeneron Pharmaceuticals

Most Recent Events

24 Mar 2025 Planned primary completion date changed from 17 May 2026 to 8 Jul 2025.
13 Mar 2025 Planned number of patients changed from 235 to 335.
13 Mar 2025 Planned End Date changed from 23 Mar 2028 to 18 Mar 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com